Speciality Generic Injectables

The Speciality Generic Injectables (SGI) division, a subsidiary of Biological E. Limited, which started in 2013, is the outcome of the company’s efforts to expand the geographical footprint of its Branded Formulations division, which is India-centric. The choice of operating in the injectables space through SGI is predicated on the company’s significant experience in sterile manufacturing. The focus of this new division will be on the development and commercialization of injectable products, primarily Non-Biological Complex Drugs, but also certain routine injectables in order to build a portfolio of both complex and routine injectable products.

The target markets for this division will be primarily the regulated markets, although other markets will be explored as its product offerings continue to evolve.

The US operations of this division commenced in 2019. BE Pharmaceuticals Inc. operates out of Cary, North Carolina, USA.


The information on this website is intended for use only by residents of the United States of America. The product information on this site is provided for general information purposes only and is not intended to be a substitute for the actual approved product information. This information is neither medical advice nor a substitute for discussions with a qualified medical professional. The products listed are available only through prescription by a qualified medical professional. BE Pharmaceuticals Inc. and its affiliates shall not be responsible for the reliance on or use of any information contained herein. The reader understands and agrees to the foregoing.

I AgreeI Decline